MINNEAPOLIS, May 8 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced participation in the upcoming Annual Meeting of the American Association for Thoracic Surgeons. One of the key gatherings of cardiovascular surgeons from around the world, the event is being held in San Diego from May 10-14, 2008.
The AATS meeting provides an excellent opportunity to demonstrate the progress made by ATS Medical in assembling an array of product offerings focused on the evolving needs of cardiac surgeons. The exhibition will feature the company's flagship ATS Open Pivot(R) Heart Valve and its newest advancement, the ATS Open Pivot(R) AP360(TM). The AP360 combines the fundamental strengths of the open pivot design with a new cuff that maximizes hemodynamic performance and extends the valve's appeal to a broader range of surgeon preferences.
The ATS 3f(R) Aortic Bioprosthesis will be the highlight of the exhibition. Professor Sven Martens from the JW Goethes University in Frankfurt will be presenting his "Single Center Experience with the ATS 3f(R) Enable(TM) Aortic Bioprosthesis" at the ATS booth on May 12 and 13.
The ATS Simulus(R) annuloplasty product line, designed for the heart valve repair market segment, will be showcased with special focus on the new ATS Simulus Semi-Rigid Annuloplasty Ring. Scott Goldman, M.D., from Lankenau Hospital in Philadelphia, will present his "Experience with ATS Simulus Annuloplasty Products and the ATS CryoMaze(TM) Surgical Ablation System" on Monday, May 12 during an in-booth presentation.
Atrial fibrillation is expected to be a key growth driver in 2008 and beyond. The ATS CryoMaze(TM) Surgical Ablation System, proven to yield clinical results similar to the conventional cut-and-sew Cox Maze III procedure, is being used by a growing number of surgeons as their therapy of choice. Edward Raines, M.D., of BryanLGH Medical Center in Lincoln, Nebraska, will present "A Practical Approach to Stand-Alone CryoMaze Prodecures via Mini-Thoracotomy" on May 13 at the ATS booth.
ATS Medical previously announced the first Frontiers in Cryoablation Symposium to be held in conjunction with the AATS on Sunday, May 11 with James Cox, M.D. and Niv Ad, M.D. co-moderating the program. Titled "Current Techniques, Robotics and the Future of Minimally Invasive Cryoablation," the symposium is sponsored collaboratively by ATS Medical and Intuitive Surgical, the makers of the da Vinci(R) Surgical System (Nasdaq: ISRG). The program will include a preeminent faculty of cardiac surgeons reporting on current techniques, robotics, and the future of minimally invasive cryoablation utilizing the ATS CryoMaze(TM) Surgical Ablation System.
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007 and its most recent quarterly report on Form 10-Q.
|SOURCE ATS Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved